Innovent and ImmVirX Expand Collaboration to Investigate TYVYT® with IVX037 in Liver Cancer

San Francisco, U.S. and SUZHOU, China, April 29, 2025 - Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, are pleased to announce the expansion of their clinical trial collaboration and supply agreement into hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. Under the expanded collaboration, ImmVirX will evaluate the combination therapy consisting of ImmVirX’s investigational oncolytic virus, IVX037, and Innovent’s TYVYT® (sintilimab injection), the market-leading anti-PD-1 inhibitor in liver cancer patients in China. The collaboration is progressing well. The ongoing Phase 1b study is actively recruiting patients across seven sites with, with additional sites to follow. To date, the study has focused on assessing the anti-cancer activity and tolerability of intra-tumoral IVX037 administered in combination with intravenous sintilimab in patients with advanced colorectal, ovarian and gastric cancers. Innovent is supplying TYVYT® (sintilimab injection) for this multi-center trial in Australia. With this expansion, an additional 15 liver cancer patients will be enrolled in the study. “We are excited to expand the current Phase 1b study of IVX037 and sintilimab to include patients with advanced Hepatocellular Carcinoma. This indication is a particularly difficult cancer to treat, with limited treatment options available for patients. We hope the encouraging outcomes observed in the completed Phase 1a and now ongoing Phase 1b studies will continue as we treat patients with HCC,” said Dr Mark Wong, Principal Investigator of the study. Dr. Hui Zhou, Senior Vice President of Innovent, stated: “We are encouraged by the early progress in the study combining IVX037 with our anti-PD-1 therapy, TYVYT® (sintilimab injection). We believe their complementary mechanisms to engage the immune system to fight cancer may also prove effective in liver cancer. We look forward to continuing our work with ImmVirX and to seeing promising results from this collaboration.” Dr Malcolm McColl, Chief Executive Officer of ImmVirX, commented: "I’m thrilled that Innovent is eager to expand our collaboration on the combination study of IVX037 with TYVYT® to additional solid tumors. Innovent is an impressive company and a strong partner during this early stage of our work together.” About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statement: （1）Innovent does not recommend the use of any unapproved drug (s)/indication (s). （2）Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company. About ImmVirX ImmVirX is developing novel oncolytic immunotherapies to create powerful new cancer therapy combinations. Our lead asset, IVX037, is in clinical studies with our second agent, IVX055, in pre-clinical development. Our novel oncolytic immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and induce local and systemic anti-tumour immune responses. The proprietary bio-selection platform enables the development of RNA viruses targeting specific receptor proteins highly expressed on a range of cancer cell types, allowing them to selectively enter, replicate in, and destroy tumour cells while creating beneficial changes in the tumour micro-environment, potentially leading to the generation of specific innate and adaptive immune responses against cancer cells. In this way, our oncolytic immunotherapies are intended to increase the effectiveness of current therapies, primarily immune checkpoint inhibitors and CAR-T cell therapies, in fighting cancers of high unmet need including colorectal, gastric, ovarian and liver cancer. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics (“Innovent”), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. Contact Innovent Media： E-mail：[email protected] Tel：+86 512-69566088 Investors： E-mail：[email protected] Tel：+86 512-69566088 ImmVirX Dr. Malcolm McColl Chief Executive Officer, Acting Chairman and Co-Founder E-mail: [email protected]

The release as fetched from its publisher. innoventbio.com ↗